Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

OTHER × MCRC × tislelizumab × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Conditions

Carcinoma, Non-Small-Cell Lung 28 Carcinoma, Hepatocellular 28 Colorectal Neoplasms 17 Stomach Neoplasms 16 Esophageal Squamous Cell Carcinoma 14 Squamous Cell Carcinoma of Head and Neck 13 Head and Neck Neoplasms 9 Lung Neoplasms 8 Esophageal Neoplasms 8 Cholangiocarcinoma 8 Triple Negative Breast Neoplasms 7 Rectal Neoplasms 7 Nasopharyngeal Carcinoma 7 Small Cell Lung Carcinoma 6 Pancreatic Neoplasms 6 Uterine Cervical Neoplasms 5 Recurrence 5 Neoplasms 5 Hodgkin Disease 5 Colonic Neoplasms 5 Urinary Bladder Neoplasms 4 Neoplasm Metastasis 3 NSCLC 3 Locally Advanced Rectal Cancer 3 Liver Neoplasms 3 Leukemia, Myeloid, Acute 3 Glioblastoma 3 Biliary Tract Neoplasms 3 Advanced Solid Tumor 3 Adenocarcinoma of Lung 3

Interventions

tislelizumab 1 regorafenib 1 Trace amine-associated receptor 1 1 Thymalfasin 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT06829355 2025-02-17

THYMI

Beijing Friendship Hospital

Phase 2 Recruiting

MCRC

Data powered by HemOnc (CC BY 4.0) Colophon ⚡